Eloxx Pharmaceuticals, Inc. Total Liabilities
Eloxx Pharmaceuticals, Inc. total liabilities. Based on the latest financial reports, Eloxx Pharmaceuticals, Inc. (ELOX) has total liabilities worth $16.97 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Eloxx Pharmaceuticals, Inc. (ELOX) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Eloxx Pharmaceuticals, Inc. (2004–2025)
Total liabilities of Eloxx Pharmaceuticals, Inc. from 2004 to 2025. This chart illustrates how Eloxx Pharmaceuticals, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Eloxx Pharmaceuticals, Inc. Competitors by Total Liabilities
The table below lists competitors of Eloxx Pharmaceuticals, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LUOYANG GLASS CO. H YC 1
F:LUG
|
Germany | €10.15 Billion |
|
Li-FT Power Ltd.
F:WS0
|
Germany | €23.25 Million |
|
Mackolik Internet Hizmetleri Ticaret A.S.
IS:MACKO
|
Turkey | TL191.45 Million |
|
CHEET.M.ADR 50 NEW
F:0C9
|
Germany | €2.73 Billion |
|
UIL Co. Ltd
KQ:049520
|
Korea | ₩83.92 Billion |
|
Transat AT Inc
TO:TRZ
|
Canada | CA$3.35 Billion |
|
TechPrecision Corporation Common stock
NASDAQ:TPCS
|
USA | $23.63 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Eloxx Pharmaceuticals, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Eloxx Pharmaceuticals, Inc. assets under control.
Liquidity & Leverage Metrics
Eloxx Pharmaceuticals, Inc. Total Liabilities Ratios Explained
Eloxx Pharmaceuticals, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eloxx Pharmaceuticals, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eloxx Pharmaceuticals, Inc. (2004–2025)
The table below shows the annual total liabilities of Eloxx Pharmaceuticals, Inc. from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $17.18 Million | -37.11% |
| 2024-12-31 | $27.31 Million | +12.34% |
| 2023-12-31 | $24.31 Million | -23.51% |
| 2022-12-31 | $31.78 Million | +39.67% |
| 2021-12-31 | $22.75 Million | +40.06% |
| 2020-12-31 | $16.25 Million | -28.53% |
| 2019-12-31 | $22.73 Million | +191.20% |
| 2018-12-31 | $7.81 Million | +128.07% |
| 2017-12-31 | $3.42 Million | -26.63% |
| 2016-12-31 | $4.67 Million | -36.29% |
| 2015-12-31 | $7.32 Million | +25.28% |
| 2014-12-31 | $5.84 Million | +81.97% |
| 2013-12-31 | $3.21 Million | -5.59% |
| 2012-12-31 | $3.40 Million | -16.60% |
| 2011-12-31 | $4.08 Million | -31.22% |
| 2010-12-31 | $5.93 Million | +307.73% |
| 2009-12-31 | $1.45 Million | +80.18% |
| 2008-12-31 | $807.28K | +27.69% |
| 2007-12-31 | $632.21K | +8.37% |
| 2006-12-31 | $583.39K | +11.46% |
| 2005-12-31 | $523.39K | +9.01% |
| 2004-12-31 | $480.12K | -- |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney dis… Read more